Oral anticoagulation on patients with atrial fibrillation: are we doing a good job?
AbstractIntroduction Atrial fibrillation (AF) is one of the major causes of stroke and cardiovascular morbidity in the world [1]. Oral anticoagulation (OAC) with vitamin K antagonists (VKAs) or non-VKA oral anticoagulants (NOACs) reduces the risk of such events in AF patients [1–3]. Our aim was to e...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2021-04-01
|
| Series: | Annals of Medicine |
| Online Access: | https://www.tandfonline.com/doi/10.1080/07853890.2021.1896844 |